Cell Biology

Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes – India Education Diary

Ottawa: There are more than 300,000 Canadians living with type 1 diabetes (T1D), an autoimmune disease with no known cause or cure, resulting in the dysfunction, damage or loss of pancreatic beta cells that produce insulin in our bodies. People with T1D must treat themselves with insulin several times per day to keep their blood glucose levels normal, and despite their best efforts, they often experience serious, and even life-threatening, complications.

To mark the end of Diabetes Awareness Month, Sonia Sidhu, Member of Parliament for Brampton South, on behalf of the Honourable Patty Hajdu, Minister of Health, announced an investment of $6 million through the CIHR-JDRF Partnership to Defeat Diabetes for two Canadian research teams to accelerate the development of stem cell-based therapies for the treatment of T1D.

Stem cells show great promise as a source of insulin-producing cells that could be transplanted to provide a new source of insulin, to replace dysfunctional, damaged or lost pancreatic beta cells. Canada has a remarkable legacy in leading discoveries in this area. Stem cells were discovered in Toronto in 1961, and in 2000, a team in Edmonton were the first to pioneer transplantation of pancreatic islets (the part of the pancreas that contains insulin-producing cells). These achievements represent important steps toward a treatment that will allow people with T1D to live healthy lives without daily insulin injections.

The research teams are led by Dr. Maria Cristina Nostro at the University Health Network and the University of Toronto and Dr. Francis Lynn at the BC Childrens Hospital Research Institute and the University of British Columbia. The teams will build on Canadas demonstrated research excellence and leadership in clinical islet transplantation, stem cell biology, diabetes, immunology and genetic engineering to accelerate stem cell-based therapies for T1D. They will work in collaboration with other Canadian researchers to tackle some of the biggest scientific challenges that impede our progress in this area and move us closer to a future where people with T1D will no longer rely on insulin therapy.

This funding was provided by the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD), and JDRF Canada, through the CIHR-JDRF Partnership to Defeat Diabetes established in 2017. Each partner will invest $3 million over five years. This investment is part of a large research initiative, 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes, funded by CIHR and partners. This initiative commemorates the 100th anniversary of the discovery of insulin to be marked in 2021a discovery that changed the lives of millions of Canadians and people around the world and won researchers Sir Frederick Banting and John Macleod the Nobel Prize in Physiology or Medicine.

More here:
Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary

Biochemistry

What are chemical signs of life beyond Earth? – Chemical & Engineering News

In brief

When astrobiologists look for physical evidence of past or present life beyond Earth, they search for biosignatures, like molecules with chemistry that doesnt make sense on the basis of nonliving processes. But determining if a molecule from another world is out of place enough to come from life means that scientists first have to understand the nonliving chemistry of the planetary body where it was found. While some scientists are developing tools like the Ladder of Life Detection to effectively evaluate biosignatures, others are trying to figure out how to differentiate biological chemistry from the rest. This conceptual work could help scientists who are analyzing data collected by missions searching for life in our solar system or beyond.

In 1976, two probes from NASA landed on Mars to conduct the first experiments in search of life beyond Earth.

The Viking 1 and 2 landers were looking for evidence of living martian microbes. They treated soil samples with nutrients or other compounds that microbes could metabolize and then monitored for molecules that indicated active biochemistry.

Initial results had scientists excited: one experiment detected radiolabeled gases emitted from samples treated with carbon-14-labeled nutrients. If information from other experiments on board the two Viking landers had not been available, this set of data would almost certainly have been interpreted as presumptive evidence for biology, writes Harold Klein, a NASA astrobiologist involved with the original Viking missions, in a paper published about the results (Icarus 1978, DOI: 10.1016/0019-1035(78)90053-2).

But other instruments on the Viking landers detected only trace amounts of organic moleculeslike chloro- and dichloromethane. The lack of complex molcules, organic or otherwise, precluded a biological explanation for the radiolabeling results. Other experiments run by the landers were inconclusive at best. After many years of intense debate, the scientific community eventually concluded that nonliving, or abiotic, processeslike unknown oxidants in the soilwere a more likely explanation for the Viking results.

These experimental results demonstrated just how challenging it can be to identify physical signs of life, or biosignatures, much less make a definitive claim for having found life on another planet. The Viking missions led scientists to develop new techniques for evaluating biosignatures and instrumentation for detecting them. But these initial experiments also caused scientists to ask: How do we determine if something is alive in the first place?

Credit: NASA/JPL

This photo of the martian landscape was taken by the Viking 1 lander on July 23, 1976.

By and large, what we do in biosignature science is chemistry, says Heather Graham, an organic geochemist at the Catholic University of America and NASAs Goddard Space Flight Center. Biosignatures can be fossilized cells or active microbial communities. But they can also be molecules that are made only by living organisms. These biosignatures are molecules that would be out of place in a planets geochemistry if it were not for some living organism churning them out.

By and large, what we do in biosignature science is chemistry.

Heather Graham, organic geochemist, Catholic University of America and NASAs Goddard Space Flight Center

Yet without understanding the fundamental chemistry of our universe, scientists cant determine whether a physical indicator is weird enough to come from life. Now, scientists are trying to figure out what distinguishes biological chemistry from other types of chemistry and how we can quantifiably detect it. This work includes reevaluating what chemists have assumed about how biochemistry evolved on Earth. Astrobiologists hope this fundamental chemical research will help researchers collect and assess data from within our solar system and beyond.

Ladder of life

Before scientists can start to look for molecular signs of life, they need to define what life is. NASAs working definition is a self-sustaining chemical system capable of Darwinian evolution. NASA scientists see life as a system of molecules that can reproduce, store information, and generate energy through metabolizing molecules in its environment.

NASA researchers have used that definition to establish a system for assessing whether a molecule or material from outer spaceor even ancient Earthis a biosignature. They call this framework the Ladder of Life Detection (Astrobiology 2018, DOI: 10.1089/ast.2017.1773). Developed by a research team led by Marc Neveu, an astrobiologist with the University of Maryland, College Park, and the Goddard Space Flight Center, the ladder consists of rungs corresponding to key features that scientists might look for in life, going from ones that are not strongly indicative of life to those that are.

The key starting point here is that life has many features, but no single feature is a telltale sign of life in and of itself, Neveu says. He thinks the ladder can help scientists think about how to compile a chain of evidence in a practical way.

For example, amino acids are the building blocks of proteins on Earth. If scientists found these molecules on another planet, that would correspond to the rung for potential biomolecule components. But thats only if amino acids cant be produced by any nonliving systems on that planet. A chemical hint of life can be deemed a biosignature only if the compound deviates from abiotic distributions, the authors write, meaning its presence or abundance doesnt make sense given the planets general geochemistry.

Ladder of Life Detection

This framework helps scientists build a chain of evidence to confirm a potential observation of life. Features on the rungs ascend from weakly (bottom) to strongly (top) suggesting a living organism has been observed. Scientists would need to find features from multiple, but not all, rungs to claim that life has been found.

Credit: Adapted from Astrobiology/C&EN/Shutterstock

Top rung: Darwinian evolution

Cultured microbes that show signs of adaptation to selective pressure would be a strong biosignature of life. These features are impractical to detect in current missions in our solar system.

Growth and reproduction

Observation of a suspected microbe at multiple stages of its life cycle would be needed to confirm growth and reproduction. Microbe motility could also indicate life on this rung.

Metabolism

Metabolic cycles can extract energy from molecules in the environment. These cycles often show a preference for certain isotopes or molecules, which change their abundance in biomass compared with the nonliving environment.

Functional molecules and structures

This class of molecules includes polymers with repeating charges or structures that might support information storage or other biological functions.

Potential biomolecule components

This category includes the smaller building blocks that could make up complex biomoleculeslike the amino acids that build proteins on Earth. Some of these monomers are not produced abiotically on Earth.

Potential metabolic by-products

These complex molecules accumu- late in a distinct way in the environ- ment or contain features that follow a pattern, suggesting a living metabolic cycle is at play. These featuressuch as the carbon accumulated in a desert shrubare more generic than those of the metabolism rung.

Bottom rung: Biofabrics

Credit: Adapted from Astrobiology/C&EN/Shutterstock

Biofabrics are structures, like mats or layered morphologies, created by microbial colonies. They can be living or fossilized and can be observed with microscopy.

It really puts a lot of the burden of proof that you found life on understanding the context of what your environment looks like and what abiotic processes that dont involve life are at play, Neveu says. The key here is to understand where the baseline is. Even if scientists can be reasonably sure that theyve detected a potential biosignature, the ladder says that life has to be the hypothesis of last resort.

Frances Westall, a geologist with Frances National Center for Scientific Research and a scientist with the European Space Agency (ESA), says the ladders usefulness can be demonstrated by applying the framework to results from past experiments.

For example, when reevaluating the Viking experiments, scientists today would place the detection of those radiolabeled gases on the rung for metabolism because the gases suggested a response to the addition of possible metabolic fuels. But the Viking experiments produced no other data that could go on the ladder. Even after scientists confirmed that the signals detected by the Viking landers instruments are real, the biosignatures fail to rule out enough abiotic processes to claim life as a last-resort hypothesis. Researchers can thus conclude that there certainly is evidence for life, just not sufficient evidence to exclude abiotic processes, Neveu says.

The key starting point here is that life has many features, but no single feature is a telltale sign of life in and of itself.

Marc Neveu, astrobiologist, University of Maryland, College Park, and NASAs Goddard Space Flight Center

Its not that an experiment should be expected to find a feature on every rung of the ladder, Neveu says, but one feature is not enough to claim that youve found an alien life-form. Neveu hopes that the ladder will help scientists designing missions in search of life think about what kinds of evidence they would need to build a case for life.

The Ladder of Life Detection is still a work in progress and is meant to spur further discussion in the astrobiology community, Neveu says. One major limitation is that the ladder centers on NASAs working definition of life. It all depends on what definition of life youre starting from, Neveu says, and thats definitely an issue that has not been resolved. The order of rungs is also up for debate. Neveu expects that scientists will continue to add features and criteria to the ladder as our understanding of chemical traces of life evolves.

The future of Mars

Despite the disappointing results from the Viking missions, Mars remains a favorite destination for astrobiologists. Though the Red Planets climate is harsh and its surface is bombarded with biology-zapping ultraviolet radiation, planetary scientists believe that Mars may have once looked a lot like Earth, coursing with rivers that could have been home to microbes.

The ESA and Russias Roscosmos are jointly planning a mission called ExoMars 2022 that will explore Oxia Planum, a region of Mars rich in clay deposits that may have been left behind by an ancient river delta. The rover, named Rosalind Franklin, is specially equipped to look for signs of past and present life.

Because the martian surface is a harsh environment for preserving organic molecules, the Rosalind Franklin will drill down 2 m below the surface to collect samples that have been protected from the elements. A suite of onboard instrumentation, including the Mars Organic Molecule Analyzer (MOMA), will then interrogate the collected samples.

The samples can be processed one of two ways. In one, a sample is heated in an oven where volatile molecules are separated by gas chromatography before entering the ion-detection trap of MOMAs mass spectrometer. This process is not ideal for large organic molecules that might break apart with heat, so MOMA also has a laser to vaporize soil samples and directly inject the released molecules into the mass spectrometer.

Credit: ESA/ATG Medialab

The Rosalind Franklin rover will search for life on Mars as part of the ExoMars 2022 mission.

Fred Goesmann, the principal investigator for MOMA and a scientist at the Max Planck Institute for Solar System Research, says the different sample preparation platforms allow MOMA to detect a broad array of organic molecules. So the researchers can start with very few assumptions on what we might encounter, Goesmann says.

Unlike the Viking experiments, the MOMA instruments arent trying to elicit a response from samples that could indicate ongoing biochemistry. Instead, the equipment is designed to look for inherent features of organic molecules that could suggest they came from living systems.

Goesmann says that when scientists look for such features, the underlying assumption is that life creates order. He says that life is choosy, meaning it prefers some molecules over others, so its presence can change the distribution of chemical species on a planet. For example, organisms on Earth prefer lighter isotopes in biomolecules, so the amount of carbon-13 and carbon-14 in organisms differs from their relative abundances on the planet in general. Such isotopic fractionation is a feature of metabolism on the Ladder of Life Detection and can easily be probed with a mass spectrometer.

Another feature of Earths biochemistry, which is also found on the ladders rungs, is a preference for chiral molecules. Most sugars and amino acids used in biology are exclusively one enantiomer, for example. Goesmanns MOMA instruments will be the first to directly analyze the chirality of organic molecules on another world. Because chiral molecules are difficult to characterize with gas chromatography/mass spectrometry, MOMA contains a tiny wet lab to modify the chiral molecules in a way that makes them distinguishable from one another and detectable in the mass spectrometer. Complex organic molecules featuring isotopic fractionation or an excess of one enantiomer could be important results for building a chain of evidence in favor of life on Mars.

In the meantime, the Perseverance rover, part of NASAs Mars 2020 mission, is equipped to prepare samples that may one day return to Earth for thorough analysis in traditional wet labs. The mission launched this summer and is scheduled to land in February 2021 at Jezero Crater, where the rover will also conduct experiments on the planet itself.

Back to the drawing board

But even as missions in search of life are planned for Mars and other bodies in our solar system, chemists on Earth continue to debate the basic molecular signs of life.

I think the assumption within the prebiotic chemistry community and much of the biological community is that metabolism is a result of evolution, says Joseph Moran, an organic chemist at the University of Strasbourg. According to this prevailing view, molecules like enzymes evolved before the metabolic cycles they perform inside cells to produce energy and build cellular components. Moran takes the opposite view. His research with enzyme-free catalysis suggests that many biochemical reactions on Earth were possible under prebiotic conditionsbefore life was present.

Credit: Adapted from Nature

Joseph Morans team found that pyruvate, glyoxylate, and ferrous iron can produce all but two (shown in black) molecules in the Krebs cycle.

For example, Moran has shown that iron can reduce carbon dioxide to form key metabolic intermediates of the reverse Krebs cycle and acetyl coenzyme A pathway, two ancient metabolic pathways that bacteria still use (Nat. Ecol. Evol. 2018, DOI: 10.1038/s41559-018-0542-2, and 2017, DOI: 10.1038/s41559-017-0311-7). His team has also found that pyruvate and glyoxylate can produce almost all components of the forward Krebs cycle in the presence of ferrous iron (Nature 2019, DOI: 10.1038/s41586-019-1151-1). I guess Ive made it a habit of trying to show that processes that we thought of as biotic can actually occur abiotically, he says.

And Moran is not the only one to argue that some biochemical reactions could have preceded life. A recent study from the Center for Chemical Evolution demonstrates how key analogs of the Krebs cycle can be produced under mild conditions without enzymes or metals (Nat. Chem. 2020, DOI: 10.1038/s41557-020-00560-7). Meanwhile, a team led by Bartosz Grzybowski, a physical organic chemist at South Koreas Institute for Basic Science, used computer algorithms to model how complex prebiotic chemical processes could have emerged from a handful of starting materials (Science 2020, DOI: 10.1126/science.aaw1955). Grzybowski previously developed software that uses chemical reaction rules to plan syntheses of complex organic molecules like pharmaceuticals. In this new study, his team taught a computer program rules based on possible prebiotic chemical reactions found in the literature and then watched what reactions it could plan starting with six simple molecules that probably existed on a prebiotic Earth. The researchers were excited when their software identified chemical cyclessynthetic routes that reproduce their starting materialsas you would expect from a rudimentary metabolism.

As chemists learn more about how chemical complexity can arise from simple mixtures of molecules, Moran and others say that astrobiologists will need to rethink what constitutes a biosignature or at least where metabolism fits on the Ladder of Life Detection.

The Laboratory for Agnostic Biosignatures (LAB) is a consortium of scientists funded by a grant from NASA to do just that. LAB is interested in looking at biosignatures that arent biased by Earths biochemistry.

Lee Cronin, a chemist with the University of Glasgow and a LAB researcher, thinks its more than likely that the chemistry that led to the existing biology on Earth is no longer evident in the biochemistry we see. This means it may be impossible to reverse engineer what prebiotic chemistry on early Earthor another planetmight have looked like solely from the life thats present today. As a result, a biosignature based on Earths current biochemistry may not help us spot signs of developing life somewhere else.

LAB is looking for agnostic biosignaturesphysical indicators that dont rely on an analogy to Earths biochemistrysuch as elemental accumulation. To understand the concept of elemental accumulation, for example, imagine an aerial view of a desert landscape peppered with sage brush, suggests NASAs Graham, LABs deputy principal investigator. The amount of carbon that has accumulated in the sage plants is significantly different from that of the surrounding landscape, indicating that some biotic processin this case, the plants growthis at work. This perspective even works down to the scale of microbes. If you think about it, thats kind of a rudimentary way of describing a cell: its a defined area where theres an accumulation and chemical abundance pattern that differs from its surrounding environment, she says. Looking for elemental accumulation patterns like these doesnt rely on an analogy to life on Earth, making it agnostic and possibly more broadly useful to astrobiologists.

Beyond Mars

Mars isnt the only extraterrestrial body where life might exist or might have once existed. Recently, our nearest planetary neighbor, Venus, intrigued astronomers when a research team led by Jane Greaves at Cardiff University reported the first signs of phosphine in the planets cloud decks (Nat. Astron. 2020, DOI: 10.1038/s41550-020-1174-4). This molecule is associated with anaerobic microbes on Earth, which had many astrobiologists excited for the possibility of alien life in the venusian atmosphere.

Phosphine could be a biosignature on Venus because it doesnt seem to belong. The planets atmosphere is highly oxidizingyet PH3 is a highly reduced molecule. In the Ladder of Life Detection, this gas is a possible feature of metabolism. New evidence suggests that the phosphine signal could be an artifact of data processing (arXiv 2020, arXiv: 2010.09761). The new study was published on a preprint server, meaning it has not yet been peer-reviewed. Even so, some critics wonder if there might be an abiotic explanation for phosphines presence on Venus.

What it [the phosphine signal] shows is something weird is going on on Venus, says Matthew Pasek, a geochemist with the University of South Florida who specializes in phosphorus chemistry. He thinks that the authors of the first paper may have been too quick to dismiss abiotic avenues for phosphine production on Venus. For example, not knowing the composition of Venuss rocky surface makes it hard to rule out the possibility that acid rain from the cloud decks volatilized phosphorus in the planets crust to produce phosphoric acid, which eventually formed phosphine. Theres just too much we dont know about Venuss geochemistry without sending missions to probe it directly, Pasek says.

Farther out in our solar system, astronomers have identified other celestial bodies that may host life. In 2026, NASA will launch a mission to Titan, an icy moon orbiting Saturn. Titan is one of the few planetary bodies in our solar system with a dense atmosphere composed of nitrogen gas and methane. Scientists are particularly intrigued by the aqueous ocean hidden below Titans icy crust. This carbon-rich sea occasionally explodes into the moons atmosphere through ice-spewing volcanoes, a process called cryovolcanism. Michael Malaska, a planetary scientist studying Titan at NASAs Jet Propulsion Laboratory (JPL), believes that the moons vast oceans and plentiful carbon make it one of the most likely places in the solar system to find life. But on an alien moon chock full of organic molecules, it will be challenging to distinguish biosignatures from complex molecules made through background carbon chemistry.

Malaska is part of a team at JPL led by planetary geologist Rosaly Lopes that is investigating how geochemical processes on the moon transport and alter carbon-based molecules. Lopes thinks the subsurface ocean is the most likely place for life to occur on Titan, so part of the teams mission is to understand what kinds of biosignatures might arise from the moons carbon-rich waters. Because of Titans complex geological processes, the researchers also have to consider how these biosignatures might be modified as they go through the ice crust and come out as either gases or part of cryolava, she says.

Sign up for C&EN's must-read weekly newsletter

The search for life beyond Earth also continues into the distant galaxy. Soon satellites like the James Webb Space Telescope will be able to study the habitability of exoplanets far outside our solar system.

What will scientists find inside or outside our solar system? Were more likely to find traces of a prebiotic system than a biological system on another planet, Westall says. She worries that we still dont know enough about the fundamentals of abiotic chemistry to suss out the in-between bits of a system with the potential to develop into biology.

Many scientists believe that given the right tools and enough time, we will find life beyond Earth. Others remain uncertain. Do I think its there? Yeah, probably, Graham says. Do I think well find it? Maybe.

The chase is half the battle, Malaska says. If we did all of this and we found out that there are no other places in the solar system that has life, that would have very huge implications. Wed have to consider how absolutely lucky we are to have had this accident happen to us.

The rest is here:
What are chemical signs of life beyond Earth? - Chemical & Engineering News

Biochemistry

Researchers study the role of viral intramembrane interactions in controlling programmed cell death – News-Medical.net

A research group from the Department of Biochemistry and Molecular Biology of the University of Valencia (UV), in coordination with the National Centre for Biotechnology (CNB) of the CSIC, has studied the role of the interactions within the membrane of proteins of viral families Herpesviridae and Poxviridae in the control of programmed cell death. The work, published in Nature Communications, could have implications for the development of treatments for viral infection, as well as the prevention of cancers associated with them.

The results of the finding, led by Dr. Luis Martnez, Ph.D. in the Department of Biochemistry and Molecular Biology, would imply that interactions within the membrane between virus proteins and the host individual could be used as therapeutic targets for the treatment of some viral infections. An agent capable of blocking such interactions would not only reduce, or even inhibit, viral replication, but also slow down the possible development of cancer associated with such infections.

Cell apoptosis (programmed cell death) is an essential process in multicellular organisms, as it contributes to the balance between cell death, proliferation and differentiation, which is relevant for the development and proper functioning of living things. This makes it a highly regulated process involving many components, including the protein family known as Bcl2 (B-cell lymphoma 2).

In order to maximize their growth, viruses in the Herpesviridae and Poxviridae families have developed mechanisms to modulate cell death in host individuals. Therefore, these viruses have proteins structurally similar to Bcl2 proteins, known as viral Bcl2, which have a transmembrane domain that allows the protein to be inserted into the target membrane to deregulate cell apoptosis.

In this study we show that viral Bcl2 proteins have a transmembrane domain (TMD) that allows them to be anchored to the mitochondrial membrane. In addition, we observed that these proteins are able to interact with each other and with other Bcl2 proteins of host individuals through this domain. Our results also indicate that these interactions are key to controlling cell death after an apoptotic stimulus such as a viral infection."

Dr. Luis Martnez, Ph.D., Department of Biochemistry and Molecular Biology

Source:

Journal reference:

Garca-Murria, A.J., et al. (2020) Viral Bcl2stransmembrane domain interact with host Bcl2 proteins to control cellular apoptosis. Nature. doi.org/10.1038/s41467-020-19881-9.

Read the original here:
Researchers study the role of viral intramembrane interactions in controlling programmed cell death - News-Medical.net

Neuroscience

How Neuroscience Is Changing The Way Your Brain Processes Fear At Work – Forbes

Neuroscientists are studying how to keep your brain from freaking out on the job.

When a frightful creature startles you, your brain may activate its fear-processing circuitry, sending your heart racing to help you escape the threat. Imagine, for example, youre weeding your garden and see a coiled water hose, but you think its a snake. The job of your brains fear-processing circuits is to help you learn from experience to recognize which situations are truly dangerous and to respond appropriately. So if the scare comes from a water hose instead of a snake, youll probably recover quickly. In more dire circumstances, however, if the coiled object is a poisonous copperhead, the brains fear response can be critical for your survival. Being able to fear is the ability to sense the danger and is the driving force to figure out a way to escape or fight back, said Cold Spring Harbor Laboratory ProfessorBo Li.

Neuroscientists know that fear memories are made in the amygdalaan almond-shaped structure deep in the brain, considered the hub for fear processing. And thats where many of their studies begin. Lis team is probing the brain circuits that underlie fear, using sophisticated neuroscience tools to map their connections and tease out how specific components contribute to learning fear. An understanding of these circuits could lead to better ways to control the overactive or inappropriate fear responses experienced by employees with anxiety disorders and those who suffer from panic attacks and post traumatic stress disorder in the workplace.

Suppose, for example, your boss walks by your desk. You hook eye contact with her, smile, and nod. She looks straight at you, but doesnt acknowledge your presence. She might as well be staring at the wall. Holy cow, you say to yourself. I must be in hot water. You shrink inside, ruminating over what you might have done to deserve this. Your heart races, and you feel shaky. Its just a few days before your performance review. Sleepless nights stalk you. You toss and turn as your brain circuits spin with worry over job security. This is your amygdala in action, making up a story from its library to help you survive.

The day of your evaluation, your boss calls you into her office, and your stomach flip-flops. You tremble the way you did in sixth grade when you were summoned into the principals office. But, to your dismay, she greets you with a smile and gives you a glowing performance evaluation. Not only are you not in hot water, she calls you a highly valued team member, a laudable successthe exact opposite of what your anxiety predicted and a feather in your career cap.

All that worry and rumination for nothing. But it has already taken a toll on your mind and body and your job performance. Studies show that 90% of the worries that our brain circuits scare us with are false alarms that never manifest. Still, the amygdala catalogues, prioritizes and remembers the negative experiences in an attempt to prevent lifes unexpected curve balls from ambushing you. If youre like most people, you believe the library of memories from the past as they show up in the present moment.

But had you thought about it (been able to keep your prefrontal cortex or rational brain online) you might have realized there are a number of benign reasons your boss didnt acknowledge you when she walked by your desk. Perhaps she was distracted by her own worries, deep in thought over an upcoming meeting or simply just didnt see you. But our brain circuits in the amygdala jump into action, focused only on the disastrous possibilities, blowing your thoughts out of proportion sending you into spirals of rumination. And you fell for it hook, line and sinker just like all of us do.

While the amygdala was once thought to be devoted exclusively to processing fear, researchers now are broadening their understanding of its role. New research out of Stanford University shows that the fear circuit extends far beyond the amygdala. Lis team has found that the amygdala is also important for reward-based learning, and as they trace its connections to other parts of the brain, they are uncovering additional complexity. It is important for formation of fearful memory, but its also important for interacting with other brain systems in a different behavior context, Li said. We think that this circuit that we discovered that plays a role in regulating fearful memory is only a tip of the iceberg. It is indeed important for regulating fearful memory, but probably is also involved in more complex behavior.

Li and his colleagues were surprised recently to find that the amygdala communicates with a part of the brain best known for its role in controlling movement. The structure, called the globus pallidus, was not known to be involved in fear processing or memory formation. But when the researcher team interfered with signaling between the amygdala and the globus pallidus in the brains of mice, they found that the animals failed to learn that a particular sound cue signaled an unpleasant sensation. Based on their experiments, this component of the fear-processing circuitry might be important for alerting the brain which situations are worth learning from, Li said.

The implications for employees with anxiety disorders or just plain harried workers are that they can worry less and focus more on their jobs, which could potentially escalate engagement, job performance and career success. Not to mention the companys bottom line.

The rest is here:
How Neuroscience Is Changing The Way Your Brain Processes Fear At Work - Forbes

Neuroscience

Learning Science, Institutional Change and ‘The Idea of the Brain’ | Learning Innovation – Inside Higher Ed

The Idea of the Brain: The Past and Future of Neuroscience by Matthew Cobb

Published in April of 2020.

There is this idea that I have. An idea that I expect will occupy most of the rest of my academic career. That idea has to do with the future of higher education, and it goes something like this:

Universities change by moving their institutional structures in ever-greater alignment with learning science.

That's it.

Institutional structures cover everything from incentives to policies to investments to organizational arrangements. Policies around hiring, tenure, and promotion (or adjunct recruiting) and decisions about which building to build (or not build) all fall within the umbrella of institutional structure.

We create and recreate our universities. Their designs and operations are not divinely decreed. We make them. And if we choose, we can make our universities operate in a way that aligns (or not) to what we are learning about how people learn.

Surely other things matter than learning science in determining the future of the university. Of course. Everything matters, from demographics to public policy to technological advancements. A theory of university change that puts learning science at its heart does not need to ignore all of these forces. This theory predicts that they will play out at an institutional level in a way that is mediated by advances in learning science.

This big idea about how universities will change - if it is a big idea - brings us to The Idea of the Brain. If we are going to put learning science at the core of a theory that attempts to predict the future of the university, we need to recognize that we are thinking about the brain. The brain, after all, is where learning happens.

The Idea of the Brain is one part intellectual history, one part an overview of neuroscience. It is helpful to ground contemporary understandings of how the brain works in centuries of thinking about its structures and function. Throughout history, humans have used different metaphors to understand the workings of the brain. These stories have progressed from the brain as analogous to a machine, to plumbing, to electrical wiring, to a telegraph, and more recently to a computer. As we know today, none of these metaphors is very accurate, and the comparison of the brain with a computer has likely set-back popular understanding of brain function.

What comes across most strongly in The Idea of the Brain is how little we still understand its workings. Cobb, a professor of biological sciences, believes we are decades if not centuries away from human-brain like artificial intelligence. Consciousness remains as much a mystery today as at the birth of the modern field of neuroscience in the 1950s. We've made astounding advances in areas such as brain imaging, yet we seem to be no closer to a theory of the brain that would allow us to replicate its functioning in silicon or software.

That we still understand so little about how the brain's physical structures evolved to create conscious thought should not dissuade us from the goal of advancing the science of learning. We may not understand the brain well enough to create true artificial intelligence, but we know a great deal about how the brain learns.

If our goal is to align our universities with learning science, one place to start is to situate the study of the brain as a foundational element of a liberal education. A cross-discipline reading of The Idea of the Brain seems like an excellent place to start.

What are you reading?

The rest is here:
Learning Science, Institutional Change and 'The Idea of the Brain' | Learning Innovation - Inside Higher Ed

Neuroscience

Neuroscience Antibodies and Assays Market Research Report 2020: Market Competition Trend and Price by Manufacturers till 2026 – Cheshire Media

The Neuroscience Antibodies and Assays Market grew in 2019, as compared to 2018, according to our report, Neuroscience Antibodies and Assays Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Neuroscience Antibodies and Assays Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Neuroscience Antibodies and Assays Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-neuroscience-antibodies-and-assays-market-2020-market-size-share-growth-trends-forecast-2025/#download-sample

The Neuroscience Antibodies and Assays Market is analysed based on product types, major applications and key players

Key product type:ConsumablesInstruments

Key applications:Pharmaceutical & Biotechnology CompaniesAcademic & Research InstitutesHospitals & Diagnostic Centers

Key players or companies covered are:Thermo FisherAbcamBio-RadMerckCell Signaling TechnologyGenscriptRockland ImmunochemicalsBioLegendSanta Cruz BiotechnologyRocheSiemens

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-neuroscience-antibodies-and-assays-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Neuroscience Antibodies and Assays Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Neuroscience Antibodies and Assays Market?4. What is the likely market forecast & how will be Neuroscience Antibodies and Assays Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Neuroscience Antibodies and Assays Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

Read the original post:
Neuroscience Antibodies and Assays Market Research Report 2020: Market Competition Trend and Price by Manufacturers till 2026 - Cheshire Media

Neuroscience

Tag: Neuroscience antibodies and assays Market – The Market Feed

Neuroscience antibodies and assays Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

The data presented in the global Neuroscience antibodies and assays market report is a compilation of data identified and collected from various sources. The scope of growth of the Neuroscience antibodies and assays market during the forecast period is identified after analyzing different data sources. The report is a valuable guidance tool that can be used to increase the market share or to develop new products that can revolutionize the market growth.

Get Sample Copy of This Report: https://www.premiummarketinsights.com/sample/BRC00017587

The analysis of the collected data also helps in providing an overview of the Neuroscience antibodies and assays industry which further helps people make an informed choice. Latent growth factors that can manifest themselves during the forecast period are identified as they are key to the Neuroscience antibodies and assays market growth. The Neuroscience antibodies and assays report presents the data from the year 2020 to the year 2027 during the base period while forecasting the same during the forecast period for the year 2020 to the year 2027.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in This Report:

Thermo Fisher Scientific, Abcam, Bio-Rad, Merck KGAA, Cell Signaling Technology, Genscript, Rockland Immunochemicals. Bio Legend, Santa Cruz Biotechnology, Tecan, F. Hoffmann-La Roche, Siemens.

To inquire about the discount available on this Report, visit @ https://www.premiummarketinsights.com/discount/BRC00017587

Global Neuroscience antibodies and assays Market by Geography:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (the United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)

This analysis provides evaluation for altering competitive dynamics:

This thorough Neuroscience antibodies and assays analysis of this shifting contest dynamics and keeps you in front of competitions; Six-year prediction assessment primarily based mostly on the way the sector is anticipated to development; Precisely which Neuroscience antibodies and assays application/end-user kind or Types can observe incremental increase prospects; Which trends, barriers, and challenges could impact the development and size of Neuroscience antibodies and assays economy; It helps to know that the vital product-type sections along with their growth;

Fundamentals of Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Neuroscience antibodies and assays Market Size2.2 Neuroscience antibodies and assays Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Neuroscience antibodies and assays Market Size by Manufacturers3.2 Neuroscience antibodies and assays Key Players Head office and Area Served3.3 Key Players Neuroscience antibodies and assays Product/Solution/Service3.4 Date of Enter into Neuroscience antibodies and assays Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Neuroscience antibodies and assays Sales by Product4.2 Global Neuroscience antibodies and assays Revenue by Product4.3 Neuroscience antibodies and assays Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Neuroscience antibodies and assays Breakdown Data by End User

Original post:
Tag: Neuroscience antibodies and assays Market - The Market Feed

Immunology

Understanding the immunology of COVID-19 – SelectScience

Watch this on-demand webinar with Dr. Petter Brodin to learn about new insights into the immune response to SARS-CoV-2

A popular SelectScience webinar that provides important new insights into the immune system responses to SARS-CoV-2 infection is now available on demand. The studies, conducted by Dr. Petter Brodin's group at Karolinska Institute in Stockholm, took a systems-level approach to analyze both the cellular and protein components involved, using methodologies including mass cytometry, flow cytometry and high-multiplex proteomics.

A longitudinal study of severe COVID-19 patients identified distinct patterns of immune cell coregulation in four different stages of the disease and demonstrated a shared trajectory of immunological recovery that may provide future biomarkers of disease progression. In an investigation of multisystem inflammatory syndrome in children (MIS-C), a relatively rare complication of SARS-CoV-2 infection in children, important differences in inflammatory response were seen between MIS-C and severe COVID-19 in adults. Moreover, while some similarities were observed between inflammatory responses in MIS-C and Kawasaki disease, important differences were also apparent, particularly in the T cell subsets involved.

Read on for highlights from the live Q&A discussion with Dr. Brodin or register to watch the full webinar on demand >>

PB: If we start with MIS-C and Kawasaki disease, then Kawasaki disease occurs in young children 2-4 years of age in the wintertime. It's a viral infection of a different kind and the thing about Kawasaki disease is that children present with a rash and sometimes heart involvement. Initially, when this MIS-C presentation started to occur, people mistook them for Kawasaki Disease. However, we've now learned that Kawasaki disease and MIS-C often involve different populations of children. MIS-C typically involves older kids, children of teenage years and often much more severe in presentation than the typical Kawasaki disease. They often have abdominal involvement with vomiting, stomach ache, and so on, which is not typical in Kawasaki disease. There are clearly clinical differences between MIS-C and Kawasaki disease.

When it comes to acute COVID and these other post-infectious conditions, they are quite distinct. Acute COVID typically begins with a respiratory infection, coughing, fever, and then, later on, might develop into a hyperinflammatory disease. At that time, during the hyperinflammatory later phases of the infection, then there can be similarities between MIS-C and acute COVID, but that is sort of in the later stages.

PB: This has been probably the most important issue to sort out since we started to learn about this new virus because what's pretty evident is that for the majority of patients and people infected with SARS-CoV-2, the infection is rather mild. A lot of people have fevers and a cough, and so on. Young children more frequently are asymptomatic, but then in all age groups, some individuals develop very severe disease. Most commonly, of course, men more than women, and older people more than young people. There is a very big variation in presentation with patients with COVID-19.

We've learned quite a bit over these past 10 months, with 30,000 papers published. There has been an extraordinary development in understanding both the virus, but also the immune response to the virus. We know now that men suffer often more severe disease than women when it comes to acute COVID, are more likely to end up in intensive care units and more likely to die. We think that this is related to differences in the immune system between men and women because the infection rate, the likelihood of being infected, is not different in men and women, as far as we know.

What are those immune system differences? There have been a couple of reports, and we know from other people's work that, for example, vaccine responses differ between men and women. We also know that many autoimmune diseases, particularly diseases such as lupus, which involves interferon responses, are much more prominent in women than in men, more common in women than in men. A lot of evidence points towards differences in men and women with respect to innate, initial antiviral immune responses, both before COVID-19 but also now.

I think that is probably the best determinant we have to date, to explain the differences in COVID-19 severity. It has to do with the ability to mount a robust early immune response to the virus, involving type 1 interferons but also other factors probably.

PB: I think that relates to the MIS-C work, which was done in children. The question implies that there are genetic differences when it comes to the likelihood of getting the infection. That particular question we have not studied. It's very difficult to study whether people are resistant to a particular virus. Those people are very difficult to find. We are looking into genetic host factors that would explain both why some children develop MIS-C, while most children obviously don't, and also those factors, genetics and other things, that might determine why an individual develops severe COVID versus a milder COVID. There has been some progress made in that area by researchers such as Jean-Laurent Casanovas Lab at the Rockefeller Institute, Helen Su at the NIH, leading a large consortium called Human Genetic Effort. Their patients with rare immunodeficiencies involving viral sensing and interferon responses have been reported and those are individuals that are very rare, but they presented with life-threatening COVID-19. That's related in general to the infection, not specifically children.

PB: My guess is that it might involve prior coronaviruses, but that remains to be determined. I believe, and I think quite a few people believe, that the coronaviruses are so abundant that not only children would carry immunity to such viruses but probably also quite a few adults. Therefore, it does not entirely, in my opinion, explain why children are so able to manage this infection without severe disease in general. I think probably this points more to differences in the immune system. If you think about it from an evolutionary point of view, or life history point of view, children are experts at responding to new pathogens because the younger a child is, the less experience that child would have, and the more able the child must be to respond to a new infection. While adult people, and especially older people, they can get by quite well by relying on their memory responses of prior exposures. Typically, older people might be less equipped to respond to new pathogens. This can be explained by many different factors, the lower number of naive cells in the adaptive immune system, thymic involution, and then lack of production of naive T cells, and so on. I think there are many different pieces to this puzzle, and we only know a little bit of that at the moment.

Q: What do you see are the biggest advantages of combining the two platforms used in your studies?

PB: Sometimes people say that immune responses don't occur in the blood, and so there's no point in looking in the blood. Instead, all the relevant responses occur in tissues. Obviously, it's true that the blood is not the main siteof immune activity; it is definitely tissue, specific responses that we cannot see in the blood. Given the fact that we can sample the blood so easily and we can collect non-determinable samples, there is real potential in detecting important signals in the blood, even if the immune response is actually going on primarily in a distal tissue, like the lung.What do we do to study the blood in the best possible way? My group has reasoned that by looking at the various components of blood and the immune cells and proteins that make up the blood immune system, and the circulating immune system, and doing that in the most comprehensive way that we can, we believe this gives us a very strong potential, sort of an ability to actually look at the immune response in younger children, or over time in a patient. This combination of technologies, the Olink platform for plasma protein measurements which gives very reproducible signals with very low background signal, and then the mass cytometry assay, which gives us very broad coverage of the immune cell components, we think it's a very strong combination of features.

Watch this on-demand webinar to find out more in-depth insights about the immune responses of COVID-19>>

Read more:
Understanding the immunology of COVID-19 - SelectScience

Immunology

Life Science Ontario Announces Recipients of the 2021 LSO Awards – Business Wire

TORONTO--(BUSINESS WIRE)--LSO today announced the recipients of its 2021 LSO Awards, recognizing outstanding individuals and companies contributing to the success of Ontarios life sciences sector. The awards will be presented during LSOs Celebration of Success Awards in February 2021.

The 2021 awardees are as follows:

The LSO Awards are an important part of the organizations mandate to advocate for Ontarios life sciences sector, by celebrating the individuals and companies behind its success.

2020 has been a difficult year for everyone; but COVID-19 has also highlighted the amazing contributions of the life sciences sector to solving some of societies largest challenges, said LSO President and CEO Dr. Jason Field. LSOs awards recognize these contributions annually and this years award recipients represent the many diverse ways our sector impacts the everyday lives of Canadians and the world in which we live through science, innovation and leadership.

To explore sponsorship opportunities, contact: admin@lifesciencesontario.ca

Biographies

Michael Julius, Former Vice President, Research at Sunnybrook Health Sciences CentreLifetime Achievement Award

Dr. Michael Julius is past Vice President, Research at Sunnybrook Health Sciences Centre (2000-2020). He created an international hub for life sciences dedicated to both discovery and commercialization. This initiative achieved a functional integration of researchers, clinicians, business and patients towards moving discoveries through the marketplace and into the clinic. He shepherded growth to a $125M annual research enterprise which spun off 15 companies over his tenure. Michael is currently partnering in the launch of a life sciences capital management fund.

Ahead of taking on his leadership position at Sunnybrook, Michael Chaired the Department of Immunology at the University of Toronto (1994-2000). He has Chaired both the Canadian Institutes for Health Research review panel for Immunology and Transplantation and Research Canada, an advocacy corporation dedicated to ensuring that the federal government supports and funds the priority of health research in Canada. He serves as a member of Scientific Advisory Boards for a number of companies and has Chaired two of Sunnybrooks spin-off companies.

Michael completed his undergraduate degree in genetics at McGill University and his doctoral work in genetics and immunology at Stanford University. Michael was recruited to the Basel Institute for Immunology supported by Hoffman La Roche, where he remained for the 13 years.

Having published over 200 research papers and reviews in his area of expertise, many of which have achieved citation records, Michael has in-depth knowledge of multiple therapeutic areas, including neuroscience, cancer, cardiovascular and immune system; and expertise across multiple platforms, including high content cellular analyses, AI, health informatics, and imaging-guided interventions and therapeutics.

Eugenia Duodu, CEO, Visions of Science Network for LearningCommunity Service Award

Eugenia Duodu is the CEO of Visions of Science Network for Learning (www.vosnl.org), a charitable organization that empowers youth from low-income communities through meaningful engagement in STEM (science, technology, engineering and math). She is an educator, speaker, community organizer and advocate who is passionate about creating equitable opportunities for youth to achieve their full potential. Eugenia Duodu holds both an honours bachelor degree in Chemistry and Biology and a PhD in Chemistry from the University of Toronto.

Anne Woods, Managing Director of Life Sciences and Healthcare, Silicon Valley BankVolunteer Award

Anne Woods is the managing director of the Life Science and Healthcare practice for Silicon Valley Bank in Toronto where she is responsible for leading the banks efforts in this sector across Canada.

Anne has close to 25 years experience in capital markets and life sciences. She began her career as a financial analyst and in 2005, went back to her roots in life sciences. Prior to joining SVB, Anne spent several years as a director with The Pangaea Group bringing insights and strategic direction to life science and healthcare clients.

In 2018, Anne joined the board of Life Sciences Ontario. She holds a BSc from McGill University, a MA from the University of Guelph and is a CFA Charterholder.

VIVE Crop Protection Inc.Life Sciences Company of the Year

Vive Crop Protection creates Precision Chemistry to expand the horizons of Precision Agriculture. Vive products are built on the patented Allosperse Delivery System, which greatly improves the targeting and performance of chemical and biological active ingredients, helping growers achieve real results. Vive Crop Protection commercially launched in 2016 and currently has five unique products available in the US market, with two more awaiting US EPA registration and one awaiting Canadian PMRA registration.

Vive anticipates launching the first-ever combination chemical/biological fungicide product in spring 2021 to US sugarbeet and corn growers. Its head office is in Mississauga and employs nearly 30 chemists, biologists and other professionals.

John Kelly, Deputy Minister, Ontario Ministry of Agriculture, Food and Rural AffairsLSO Leadership Award

Dr. John Kelly currently serves as Deputy Minister for the Ontario Ministry of Agriculture, Food and Rural Affairs. He was recently Chief Innovation Officer for Bioenterprise Corporation. Dr. Kelly has an extensive background working with entrepreneurs and innovation in human health and life sciences, agriculture, food and bio-economy sectors in domestic and international markets, with focus on innovation development and implementation, actively advancing products and technologies. An extensive publisher, he has authored hundreds of research and extension publications throughout his career, attracted several million dollars in investment and been a serial entrepreneur and investor. He has a wealth of experience in the private and public sector and has held various executive positions with start-ups, venture capital, multinational companies and not-for-profits, including KeliRo Company Inc., Bioenterprise Capital, DNAstack, KiKi Maple Water, Ontario Fruit & Vegetable Growers Association, MaRS Landing, Land OLakes, Rhone-Poulenc Canada Inc. and Aventis CropSciences Inc. He has also served on numerous Board of Director appointments including with Life Sciences Ontario, Canada Foundation for Innovation, Ontario Genomics, Ontario Hazelnut Association, Ontario Lavender Association and others. Dr. Kelly holds a B.Sc. (Agr). and Ph.D. from the University of Guelph and a Master of Science from the University of Alberta. He has also held Adjunct Professorships in the Department of Animal Biosciences and the Department of Plant Agriculture at the University of Guelph.

ABOUT LIFE SCIENCES ONTARIO (LSO)

Life Sciences Ontario (LSO) is a member-funded, not-for-profit organization with a legacy of more than 30 years advancing the success of Ontarios life sciences sector. LSO collaborates with government, academia, industry, and other life sciences organizations in Ontario and across Canada to promote and encourage commercial success throughout the sector. The organization provides a wide range of networking and educational events and operates a mentorship program that is helping to develop highly skilled talent and build new business opportunities for the life sciences sector. In addition, LSO launched the Life Sciences Ontario Scholarship Program, the program awards students financial benefits and an opportunity to connect with a professional from the life sciences sector. LSO is an effective conduit for delivering policy options to governments, and its dedicated to promoting Ontarios life sciences sector internationally. For more information, please visit https://lifesciencesontario.ca.

Continue reading here:
Life Science Ontario Announces Recipients of the 2021 LSO Awards - Business Wire

Immunology

The Cat Allergy market to grow incomparably in the next decade – The Market Feed

Cat is considered as beloved pet and a common source of allergens. Cat allergens are allergic to human and are generally found in cat saliva and are identified as glycoproteins. Most common allergen (glycoprotein) secreted by cat includes Fel d 1 (secreted by sebaceous gland) and Fel d 4 (secreted from cat saliva). Most common symptoms of allergic reaction to cat includes watering eyes, sneezing, chapped lips, wheezing, chest tightening, nasal congestion and itching. National Institute of Health stated that people with chronic respiratory disease (asthma, COPD, CFTR) are at a high risk for developing cat allergy. Cat allergies can be diagnosed by skin-prick tests, blood tests and patients medical history. Treatment options available for cat allergy includes antihistamine and decongestants medication. Sometimes synthetic epitope vaccine is considered an ultimate choice to treat cat allergy for long term relief.

For more insights into the Market, request a sample of this report @https://www.persistencemarketresearch.com/samples/21235

American Academy of Allergy, Asthma & Immunology, stated that allergies to cats occur in approximately 15% of the American population yearly. It has also stated, in 2014, that an estimated 14 percent of children between the age of 6 years and 19 years of age are allergic to cats. Moreover, in 2014, American Academy of Allergy, Asthma & Immunology, published that 33% of the U.S. households own at least one cat at home.

As mentioned above, people with chronic respiratory disease are at high risk for developing cat allergy. Thus, with rising chronic respiratory disease patient the global market for cat allergy treatment is also experiencing a significant growth worldwide. As an instance, emphysema (COPD) and asthma are considered as a major factor that can cause cat allergy among the global population at a significant rate. According to the Centers for Disease Control and Prevention (CDC), in 2012, North America accounted for the highest number of COPD cases in the world. The American Academy of Allergy, Asthma, and Immunology, estimated in 2012 that, more than 100 million people would suffer from asthma across the world by 2025. Thus, rising prevalence of respiratory disorders would accentuate the global market demand of cat allergy treatment.

For Information On The Research Methodology request here @https://www.persistencemarketresearch.com/methodology/21235

North America and Europe was observed to be the largest cat allergy treatment market due to high prevalence rate of cat allergy reported in these regions. Moreover, technological improvement in diagnostic test and strong demand of diagnostic test would also account for the market growth in these regions. In addition, favorable initiatives taken by federal government also accounted for cat allergy treatment market growth in North American and European region. Similarly, Asia-Pacific is considered as an untapped market due to lack of proper diagnostic facilities in some Asian countries (India, Pakistan, Bangladesh and Afghanistan). Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in healthcare infrastructure. Similarly, Asia-Pacific is considered as an emerging market due to growing market penetration in this region. Rest of the world (RoW) holds fourth position in the global cat allergy treatment market due to poor economic and health condition in most of the African countries.

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/21235

Major market players involved in manufacturing the therapeutic treatment product of cat allergy and contributing the global market share includes Glaxo SmithKline plc, Bristol Meyers Squibb, Aventis Pharmaceuticals, Pharmacia Upjohn Co., and Merck & Co. among others.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

See the original post:
The Cat Allergy market to grow incomparably in the next decade - The Market Feed